You're asking about **2-(2,5-dioxo-4-imidazolidinyl)-N-(1-naphthalenyl)acetamide**, also known as **N-(1-naphthalenyl)-2-(imidazolidine-2,4-dione-4-yl)acetamide**.
This molecule is a **synthetic compound**, not a naturally occurring one. It's important to note that the name itself doesn't immediately tell us about its specific function or significance in research.
**To understand its importance, we need more context.**
**Possible Reasons for Research Interest:**
* **Potential Biological Activity:** The molecule's structure suggests potential interactions with biological systems. The imidazolidine-2,4-dione moiety (also known as hydantoin) is found in various drugs and has known pharmacological properties.
* **Novel Drug Candidate:** It could be a potential drug candidate for treating various diseases, especially those related to the hydantoin pharmacophore.
* **Probing Biological Pathways:** The molecule might be used as a tool to study specific biological pathways or target proteins.
* **Chemical Synthesis Development:** It could be a target molecule for developing new synthetic methods or exploring the reactivity of hydantoin derivatives.
**To find out the specific reasons for research interest, we need to:**
* **Consult scientific publications:** Search for research papers that mention this molecule.
* **Check databases:** Look for entries in chemical databases like PubChem, SciFinder, or Reaxys.
* **Contact experts:** Reach out to researchers in relevant fields (e.g., medicinal chemistry, organic synthesis, or related biology).
**Without more information, it's impossible to give a definitive answer regarding its importance.** However, based on its structure and the known properties of related compounds, it likely has potential applications in various research areas.
ID Source | ID |
---|---|
PubMed CID | 2958453 |
CHEMBL ID | 1419612 |
CHEBI ID | 120570 |
Synonym |
---|
CBKINASE1_007526 |
smr000077367 |
2-(2,5-dioxo-4-imidazolidinyl)-n-1-naphthylacetamide |
MLS000064649 , |
CBKINASE1_019926 |
CHEBI:120570 |
AKOS000268132 |
BRD-A02214146-001-01-5 |
2-(2,5-dioxoimidazolidin-4-yl)-n-naphthalen-1-ylacetamide |
HMS2444J07 |
CHEMBL1419612 |
Q27208695 |
2-(2,5-dioxo-4-imidazolidinyl)-n-(1-naphthalenyl)acetamide |
SR-01000280086-1 |
sr-01000280086 |
Class | Description |
---|---|
imidazolidine-2,4-dione | An imidazolidinone with oxo groups at position 2 and 4. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 0.3162 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
geminin | Homo sapiens (human) | Potency | 0.5174 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 15.8489 | 0.0003 | 11.4484 | 31.6228 | AID900 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 31.6228 | 0.0200 | 10.7869 | 31.6228 | AID912 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |